

Answer to reviewers:

**All the corrections requested in the main manuscript are done.**

Reviewer 1:

This review was expounded noteworthy published data involving the use of additional lines of the therapy after failure of standard frontline therapies in patients with aGC. According to current situation of the therapy in advanced Gastric Cancer (aGC), not amenable to curative surgery the author suggested that patients who progress beyond second-line therapy, treatment should be considered very carefully, as to avoid unwanted toxicities that would do more harm than good. Apatinib and Pembrolizumab offer considerable opportunities for the near future, but their value is still to be weighed in larger trials. The review contains some new information and suggestions about therapy of aGC which is helpful for clinical treatment of aGC.

**Answer 1: No correction requested .**

Reviewer 2 :

Authors reviewed the chemotherapeutic progress of advanced gastric cancer. 1.They had better depict a graphic picture, which vividly shows targets for different monoclonal antibodies.

**The graphic picture was added.**

2.Spelling errors need to be corrected. In page 3: "there was no solid solid evidence that" should be "there was no solid evidence that"; Page7: "It remains unclear wether the absence of perceivable benefit" should be "It remains unclear whether the absence of perceivable benefit"; and so on.

**All the spelling errors were corrected.**

3.Table 1 should be cited in the context.

**Table 1 was cited in the context.**

4.Table 2 is missing.

**Table 2 was added.**